Organon (OGN)
Commercializes women's health medicines, biosimilars, and established brands.
Something off on this page? Send us feedback.
Commercializes women's health medicines, biosimilars, and established brands through an international footprint. A Merck spin-off, it serves conditions affecting women uniquely, disproportionately, or differently.
Women's Health, biosimilars, and Established Brands form the three business components. The portfolio combines medicines and solutions for conditions that affect women uniquely, disproportionately, or differently with mature branded medicines and biosimilars.
Built through the 2021 separation from Merck, the company operates with an international commercial footprint and roots in Organon's hormonal-medicine lineage. Targeted additions included Dermavant and its VTAMA dermatology therapy; JADA was sold to Laborie in 2026.
Operations are shaped by a pending Sun Pharma merger that requires stockholder, antitrust, foreign-investment, and other closing approvals. OGN remains NYSE-listed unless and until the transaction closes.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | Downgrade | ||
| Apr 28, 2026 | Piper Sandler | Upgrade | ||
| Apr 27, 2026 | Piper Sandler | Target | Target: $5 | Target: $14 |
| Apr 10, 2026 | BNP Paribas | Target | Target: — | Target: $12 |
| Feb 24, 2026 | Barclays | Reiterate | Rating: —Target: $7.50 | Target: $8 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $1.13B · Total debt $8.55B · Total assets $13.18B · Shareholders' equity $1.01B
- Revenue
- $1.56B
- Operating income
- $323.0M
- Net income
- $108.0M
HistoryDividendAnnual yield
| Institutions | 84.56% | 222.06M shares | |
|---|---|---|---|
| 661 holders · as of Jun 30, 2026 | |||
| Insiders | 0.50% | 1.31M shares | |
| 14 holders · as of Aug 12, 2026 | |||
| Other | 14.94% | 39.25M shares | |
| remainder | |||
262.61M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 12.21% | 32.06M | as of Jun 30, 2026 |
Pentwater Capital Management LPInstitution | 6.89% | 18.10M | as of Jun 30, 2026 |
Vanguard Portfolio Management LLCInstitution | 5.76% | 15.13M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 4.54% | 11.91M | as of Jun 30, 2026 |
State Street CorpInstitution | 3.68% | 9.66M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 5, 2026 | Juliana Papa Drinane | officer: Head of Mfg & Supply | −14,761 | $13.57 |
| May 6, 2026 | Lynette Holzbaur | officer: SVP and Corporate Controller | +26,448 | $13.35 |
| May 6, 2026 | Lynette Holzbaur | officer: SVP and Corporate Controller | −26,448 | $13.35 |
| Nov 12, 2025 | Carrie Smith Cox | director, officer: Executive Chair | +65,400 | $7.67 |
- AbbVie
Reference biologic in Organon's largest biosimilar franchise
- Amgen
Reference biologics in immunology, bone disease, and oncology
- Teva (ADR)
Generics and biosimilars in price-sensitive drug markets
- Incyte
Topical immunology therapy for atopic dermatitis
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Organon | $13.69 | +0.07% | $3.59B | 17.8 | 3.9 | 0.6 | +0.5% |
| AbbVie | $265.87 | +0.53% | $467.37B | 74.5 | 17.5 | 7.3 | +10.2% |
| Amgen | $407.38 | +3.62% | $212.19B | 24.4 | 17.4 | 5.6 | +9.7% |
| Teva (ADR) | $39.37 | −1.72% | $46.66B | 66.8 | 14.0 | 2.7 | −0.8% |
| Incyte | $126.63 | +1.59% | $25.27B | 15.9 | 52.4 | 4.3 | +37.7% |
| Median | 45.6 | 17.4 | 5.0 | +9.9% |